July 26th 2024
Findings from the phase 2 NeoPembrOV study supported the addition of pembrolizumab to neoadjuvant chemotherapy before surgery in high-grade serous ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Approves Niraparib As Frontline Maintenance in Advanced Ovarian Cancer
April 29th 2020"This approval is an important step forward in the treatment of ovarian cancer. In my opinion, maintenance treatment with niraparib should be considered an option for appropriate patients who responded to first-line platinum-based chemotherapy versus active surveillance."
Read More
Two Analyses Describe Patient Preferences for Maintenance Therapy in Ovarian Cancer
April 25th 2020In an interview with Targeted Oncology, Charlotte Sun, DrPH, MPH, discussed the findings from 2 abstracts from the 2020 SGO Annual Meeting on patient preferences for maintenance therapy in ovarian cancer and how these findings can be applied to practice in the community oncology setting.
Read More
Dostarlimab on the Road to Progress in dMMR Endometrial Cancer
April 24th 2020“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”
Read More
Novel Monoclonal Antibody Demonstrates Clinical Activity in Gynecologic Malignancies
April 23rd 2020"We are seeing clinically meaningful monotherapy activity of DKN-01 in heavily pre-treated endometrial cancer and carcinosarcoma populations, including a complete response, a partial response, and durable tumor reductions in many patients. In combination with paclitaxel, DKN-01 is generating durable responses and disease control in paclitaxel-experienced patients."
Read More
FDA Approves cobas HPV Test for Measurement of Cervical Cancer Risk in Women with High-Risk HPV
April 21st 2020"The approval of our HPV test for the cobas 6800 and 8800 Systems enables molecular laboratories to achieve the efficiency and scale they need to meet the demands of high-volume cervical screening programs..."
Read More
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
April 17th 2020Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.
Read More
Niraparib Grabs Regulatory Attention in China for Treatment of Advanced Ovarian Cancer
April 16th 2020Niraparib was granted Priority Review in China as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, by the National Medical Products Administration.
Read More
Veliparib Spotlighted for Antitumor Efficacy in Ovarian Cancer
April 15th 2020In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.
Read More
Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer
April 14th 2020Relapse-free survival was prolonged in patients with stage III/IV ovarian cancer who received frontline maintenance treatment with Vigil immunotherapy compared with placebo. This was especially true for patients with BRCA1/2 wild-type disease, according to results from the phase II VITAL study.
Read More
Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity
April 13th 2020Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II OVARIO trial.
Read More
Following its success in the phase III PRIMA study, frontline niraparib maintenance demonstrated positive patient-reported outcomes, as well as met biomarker-defined and other secondary endpoints, according to 3 analyses to be reported as part of the Society of Gynecologic Oncology 2020 Annual Meeting.
Read More
FDA Grants Fast Track Designation to Balstilimab in Metastatic Cervical Cancer
April 8th 2020The FDA has granted Fast Track designation to balstilimab, an investigational anti-PD-1 agent for the treatment of patients with cervical cancer, based on comprehensive data that suggest balstilimab can fill an unmet medical need in the space, Agenus, Inc announced in a press release. In light of the new designation, the company now plans to submit 2 Biologic License Applications in 2020, for this indication and the other for the combination of balstilimab and zalifrelimab in metastatic cervical cancer.
Read More
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
April 7th 2020The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Read More
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
March 30th 2020An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
Read More
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
March 30th 2020A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
Read More
Investigational Anti-Cancer Agent Elicits Responses in Platinum-Resistant Ovarian Cancer
March 26th 2020Treatment with an investigational targeted anti-cancer gene-therapy agent, VB-111, in addition to paclitaxel met the pre-specified efficacy criterion of an absolute percentage advantage of 10% or higher CA-125 response rate in patients with platinum-resistant ovarian cancer, according to results from the planned interim analysis of the phase III OVAL trial.<br />
Read More
Cetuximab Plus Chemotherapy Worsens Survival in Resectable Colorectal Liver Metastases
March 24th 2020Despite demonstrating improvement in overall survival as treatment of patients with advanced inoperable metastatic colorectal cancer, cetuximab plus chemotherapy led to significantly worse survival for patients with operable colorectal liver metastases in the perioperative setting, according to findings from randomized phase III clinical trial.
Read More